Tag: licensing deals

M&A and Licensing Effects on Trials: What Clinical Leaders Need to Know Now The dynamics of mergers and acquisitions (M&A) and licensing agreements within the pharmaceutical and biotechnology industries significantly influence clinical trial operations. Understanding these effects is crucial for clinical operations, regulatory affairs, and medical affairs professionals who navigate the complexities of drug development….

Read More “M&A and Licensing Effects on Trials: What Clinical Leaders Need to Know Now” »

How to Model M&A and Licensing Effects on Trials for Global Study Portfolios The dynamics of mergers and acquisitions (M&A) and licensing deals in the biopharmaceutical industry have far-reaching implications on clinical trials, particularly in a global context. The ability to effectively model these effects is crucial for clinical operations, regulatory affairs, and medical affairs…

Read More “How to Model M&A and Licensing Effects on Trials for Global Study Portfolios” »

M&A and Licensing Effects on Trials in Practice: Benchmarks, Case Studies and Playbooks The landscape of clinical research is constantly evolving, with mergers and acquisitions (M&A) and licensing agreements shaping the way clinical trials are conducted. This article provides a comprehensive view of how M&A and licensing impact clinical trials in practice, including benchmarks and…

Read More “M&A and Licensing Effects on Trials in Practice: Benchmarks, Case Studies and Playbooks” »

High-Impact M&A and Licensing Effects on Trials Strategies That Protect Trial Timelines and Margins High-Impact M&A and Licensing Effects on Trials Strategies That Protect Trial Timelines and Margins The landscape of clinical trials is evolving rapidly, influenced significantly by mergers, acquisitions (M&A), and licensing agreements. These high-impact business strategies can profoundly affect trial planning, execution,…

Read More “High-Impact M&A and Licensing Effects on Trials Strategies That Protect Trial Timelines and Margins” »

Linking M&A and Licensing Effects on Trials to Market Access, HTA and Payer Expectations Linking M&A and Licensing Effects on Trials to Market Access, HTA and Payer Expectations Introduction The landscape of clinical research has evolved significantly over recent years, with mergers and acquisitions (M&A) playing a pivotal role in shaping the paths of development…

Read More “Linking M&A and Licensing Effects on Trials to Market Access, HTA and Payer Expectations” »